2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).

Skowronski DM., Zhan Y., Kaweski SE., Sabaiduc S., Khalid A., Olsha R., Carazo S., Dickinson JA., Mather RG., Charest H., Jassem AN., Levade I., Hasso M., Zelyas N., Gao R., Bastien N.

The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).

DOI

10.2807/1560-7917.ES.2024.29.7.2400076

Type

Journal article

Journal

Euro Surveill

Publication Date

02/2024

Volume

29

Keywords

Influenza, Omicron, SARS-Co-V-2, XBB.1.5, observational study, test-negative design, vaccine effectiveness, Humans, Influenza, Human, Seasons, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Vaccine Efficacy, Canada, Influenza Vaccines, Sentinel Surveillance, COVID-19, Vaccination, Case-Control Studies

Permalink Original publication